Webinar Overview
This presentation was originally delivered at TIDES Asia 2026.
Nuclear Magnetic Resonance (NMR) spectroscopy is a powerful and versatile tool for structural characterization, offering atomic-level resolution, sensitivity to subtle (stereo)chemical differences, and inherently quantitative data. As biopharma shifts toward complex modalities such as peptides and antisense oligonucleotides (ASOs), collectively referred to as TIDES, recent advances in NMR technology, including the Multi Nuclear Inverse (MNI) probe, enable improved sensitivity and resolution for challenging biomolecules, supporting insight into conformation, stereochemistry, and molecular interactions across development and selected QC and characterization activities.
Thursday, February 26 2026
2:15 PM JST
What to Expect
As patents on key peptide therapeutics near expiration, there is increasing pressure to develop both next-generation molecules and high-quality generics, requiring analytical methods that are robust, precise, and scalable across discovery, development, and manufacturing. This presentation explores how NMR, supported by technologies such as the MNI probe, contributes to the structural characterization of peptide and ASO therapeutics, illustrated through real-world case studies from the TIDES landscape.
Key Learning Points
- The role of NMR in the structural and chemical characterization of peptides and antisense oligonucleotides
- How improved sensitivity and resolution support the analysis of complex TIDES molecules and complement other analytical techniques
- How NMR data supports development, characterization, and selected quality control activities
Who Should Attend?
- Scientists working in peptide or oligonucleotide research and development
- Analytical chemists and structural characterization specialists
- Researchers involved in biopharmaceutical development or comparability studies
- Professionals supporting analytical strategy, characterization, or quality assessment of TIDES
Speakers
Shubhadra Pillay
Structural Biologist and Solutions Product Manager at Bruker BioSpin
Specialized in protein NMR spectroscopy, molecular biophysics, and structure-based drug design. She earned her PhD from Nanyang Technological University (Singapore) and completed postdoctoral training at the Max Planck Institute for Biophysical Chemistry, focusing on protein dynamics. Dr. Pillay has contributed to the structural characterization of diverse biological systems, including viral fusion proteins and transcription-related complexes, and previously co-led biophysics efforts in fragment-based drug discovery at Takeda Pharmaceuticals. Her work bridges academic research and industry-driven pharmaceutical innovation.